Zeynep BIYIKLI, Saba KİREMİTÇİ, Gülşah KAYGUSUZ, Duygu KANKAYA, Işınsu KUZU

Is CD117 Expression Related with Plasma Cell Differentiation, IRF4/MUM1 and CD38 Expressions in Lymphoid Neoplasms?

Aim: In this study, we aimed to assess the expression of CD117 in a large series of both Hodgkin´s and non-Hodgkin´s lymphoma, and to investigate the association between the expression patterns of CD117, IRF4/MUM1, and CD38. Materials and Methods: A total of 237 lymphoma cases were selected and examined within six tissue microarray paraffin blocks. Immunohistochemistry was performed using antibodies against CD117, IRF4/MUM1 and CD38. Results: CD117 and IRF4/MUM1 immunoreactivity were seen in a subset of high-grade and low-grade B-cell lymphomas, as well as T-cell lymphomas and classical type Hodgkin´s lymphomas. CD38 positivity was only detected in 1% of diffuse large B-cell lymphoma and 66% of precursor B-lymphoblastic lymphoma, in addition to myeloma cases. CD117 expression was not correlated with IRF4/MUM1 expression (P > 0.05). Two of three CD38- positive cases were positive for CD117. Conclusions: These results suggest that CD117 expression can be seen in a subset of T- or B- cell lymphoid neoplasms and plasma cell myelomas. It seems that there is no relation between the expression of CD117 and plasma cell differentiation markers in lymphomas.

Anahtar Kelimeler:

CD117 expression, lymphoma, CD38 reactivity, plasma cell differentiation, IRF4/MUM1 expression

Is CD117 Expression Related with Plasma Cell Differentiation, IRF4/MUM1 and CD38 Expressions in Lymphoid Neoplasms?

Keywords:

CD117 expression, lymphoma, CD38 reactivity, plasma cell differentiation, IRF4/MUM1 expression,

PDF

___

Vakiani E, Giorgio C, Colovai AI, Murty VV, Alobeid B, Bhagat G. CD117 expression in diffuse large B-cell lymphomas: fact or fiction? Pathol Int 2005; 55: 716-23.
Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO Classification of Tumours, Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
Re D, Wickenhauser C, Ahmadi T. Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin’s disease. Br J Cancer 2002; 86: 1333-5.
Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998; 29: 498-504.
Tomeczkowski J, Beilken A, Frick D, Wieland B, Köniq A, Falk MH et al. Absence of c-kit receptor and absent proliferative response to stem cell factor in childhood Burkitt’s lymphoma cells. Blood 1995; 86: 1469-80.
Choe YS, Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB et al. c-kit expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas. Leuk Lymphoma 2006; 47(2): 267-70.
Brauns TC, Schultewolter T, Dissemond J, Maschke J, Goos M. c- kit expression in primary cutaneous T-cell lymphomas. J Cutan Pathol 2004; 31: 577-82.
Pruneri G, Ponzoni M, Ferreri AJM, Freschi M, Tresoldi M, Baldini L et al. The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology 2006; 48: 529-35.
Potti A, Ganti AK, Koch M, Levitt R, Mehdi SA. Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma. Leuk Lymphoma 2002; 43: 2427-30.
Lugli A, Went P, Khanlari B, Nikolova Z, Dirnhofer S. Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. Virchows Arch 2004; 444: 264- 8.
Carbone A, Gloghini A, Gaidano G, Franceschi S, Capello D, Drexler HG et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin’s disease. Blood 1998; 92: 2220-8.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
Bai M, Panoulas V, Papoudou-Bai A, Horianopoulos N, Kitsoulis P, Stefanaki K et al. B-cell differentiation immunophenotypes in classical Hodgkin’s lymphomas. Leuk Lymphoma 2006; 47: 495- 501.
Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-92.
Chang CC, Lorek J, Sabath DE, Li Y, Chitambar CR, Logan B et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002; 100: 4671-5.
Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol 2005; 32: 227-34.
Valsami S, Pappa V, Rontogianni D, Kontsioti F, Papageorgiou E, Dervenoulas J et al. A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin’s lymphoma: a potential prognostic role of MUM1/IRF4. Haematologica 2007; 92: 1343-50.
Natkunam Y, Warnke RA, Montgomery K, Falini B, van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001; 14: 686-94.
Tsuboi K, Lida S, Inagaki H, Kato M, Hayami Y, Hanamura I et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000; 14(3): 449-56.